<DOC>
	<DOCNO>NCT01788358</DOCNO>
	<brief_summary>This study examine long term safety efficacy Fixed Dose combination BAY98-7106 ( nifedipine plus candesartan primarily high dose development ) patient moderate severe hypertension . Patients meet entry criterion , receive Fixed Dose combination 28 week , include 8 week stepwise dose increase high target dose . The first 200 subject complete 28 week continue treatment additional 24 week ( 52 week total ) . Subjects tolerate increase dose treat high tolerable dose .</brief_summary>
	<brief_title>Open-Label Long-Term Safety Efficacy Study Fixed Dose Combination Nifedipine Gastrointestinal Therapeutic System Candesartan Cilexetil Subjects With Moderate Severe Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Nifedipine</mesh_term>
	<mesh_term>Candesartan</mesh_term>
	<mesh_term>Candesartan cilexetil</mesh_term>
	<criteria>Subjects must moderate severe essential hypertension ( Grade 2 Grade 3 , WHO classifications ) . At Visit 1 , subject treat antihypertensive medication MSSBP &gt; /= 160 mmHg &lt; 200 mmHg , measure calibrate electronic BP measuring device . For subject treat antihypertensive medication , MSSBP &gt; /= 160 mmHg &lt; 200 mmHg wash . Women childbearing potential men must agree use adequate contraception hormonal contraceptive sexually active Mean seat systolic blood pressure &gt; /= 200 mmHg and/or mean seat diastolic blood pressure &gt; /= 120 mm/Hg Mean seat diastolic blood pressure &lt; 60 mm/Hg Differences great 20 mmHg systolic blood pressure 10 mmHg diastolic blood pressure present 3 consecutive blood pressure reading visit 0 Any history hypertensive emergency Evidence secondary hypertension coarctation aorta , pheochromocytoma , hyperaldosteronism , etc . Cerebrovascular ischemic event ( stroke , transient ischemic attack [ TIA ] ) within previous 12 month History intracerebral hemorrhage subarachnoid hemorrhage History hypertensive retinopathy know KeithWagener Grade III IV Any history heart failure , New York Heart Association ( NYHA ) classification III IV Severe coronary heart disease manifest history myocardial infarction unstable angina last 6 month prior visit 0 Type 1 diabetes mellitus ( DM ) poorly control Type 2 DM evidence HbA1C great 9 % visit 0 . Hyperkalemia : potassium upper limit normal laboratory range</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Drug combination</keyword>
	<keyword>Nifedipine GITS</keyword>
	<keyword>Candesartan Cilexetil</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Combination therapy</keyword>
</DOC>